golcadomide

Sponsor Bristol Myers Squibb CO · listed as BMY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

golcadomide is a clinical-stage drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 9, 2027 (day precision, medium confidence), tied to trial NCT06356129. The asset is in Phase 3 and currently active not recruiting, studied in Large B-cell Lymphoma. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-08-09

As disclosedAug 9, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06356129

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorCelgene

Listed asBMY

Condition(s)Large B-cell Lymphoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More BMY catalysts